- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00739453
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study will open with Schedule 1 (S1), in which OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2. A treatment period is defined as 21 days.
Initiation of Schedule 2 (S2), in which OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity >/= grade 2 in any patient on S1 or after > 2 dose levels in S1 have been examined without evidence of Dose Limiting Toxicities (DLT).
Initiation of Schedule 3 (S3), in which OSI-906 is administered twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity >/= grade 2 in any patient on S2 or after > 2 dose levels in S2 have been examined without evidence of DLT.
Once the phase 2 dose has been established for S3, 1 expansion cohort will be opened.
The Expansion Cohort will enroll approximately 30 evaluable patients with stage IIIB/IV Non-small Cell Lung Carcinoma (NSCLC). Patients in the NSCLC Expansion Cohort will be required to have either archival tissue or fresh tumor tissue available at the start of study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Oxford, Regno Unito, OX3 7LJ
- University of Oxford Department of Medical Oncology
-
-
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University of Colorado Health Science Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21231
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Hudson-Webber Cancer Research Center, Karmanos Cancer Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor
- For the NSCLC Expansion Cohort, a confirmed diagnosis of stage IIIB/IV NSCLC after failure of at least 1 prior chemotherapy regimen is required
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status </= 2
- Predicted life expectancy >/= 12 weeks
Patients may have had prior therapy, providing certain conditions are met:
- Chemotherapy: A minimum of 3 weeks (4 weeks for carboplatin or investigational anticancer agents and 6 weeks for nitrosoureas and mitomycin C) must have elapsed between the end of treatment and registration into this study. Patients must have recovered from any treatment-related toxicities (except for alopecia, fatigue, and grade 1 neurotoxicity) prior to registration.
- Hormonal therapy: Patients may have had prior anticancer hormonal therapy provided it is discontinued prior to registration into the study. However, patients with prostate cancer with evidence of progressive disease may continue on therapy that produces medical castration (eg, goserelin or leuprorelin), provided this therapy was commenced at least 3 months earlier.
- Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration. A minimum of 21 days must have elapsed between the end of radiotherapy and registration into the study unless the radiation affected less than 25% of bone marrow.
- Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration.
- Fasting glucose </= 125 mg/dL (7 mmol/L) at baseline and on Day 1 prior to dosing
- Blood ketones </= Upper Limit of Normal (ULN)
- Neutrophil count >/= 1.5 x 10^9/L
- Platelets >/= 100 x 10^9/L
- Bilirubin </= 1.5 x ULN
- AST and/or ALT </= 2.5 x ULN or </= 5 x ULN if patient has documented liver metastases
- Serum creatinine </= 1.5 x ULN
- Patients must be nonsmokers (or former smokers who stopped smoking > 3 months previously) and have a negative cotinine test at baseline and on Day 1
- Patients in the NSCLC Expansion Cohort must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
- Patients in the NSCLC Expansion Cohort will be required to have either an archival or fresh tumor tissue (whole or partial block) available at the start of study
- Patients must be accessible for repeat dosing and follow-up, including pharmacokinetic sampling
- Patients - both males and females - with reproductive potential must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test at baseline and on Day 1
- Patients must provide verbal and written informed consent to participate in the study
Exclusion Criteria:
- Documented history of diabetes mellitus
- History of significant cardiac disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; QTc interval > 450 msec at baseline; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
- History of cerebrovascular accident (CVA) within 12 months prior to registration or that is not stable
- Prior epidermal growth factor receptor (EGFR) or insulin like growth factor receptor (IGFR) inhibitor therapy, except for prior erlotinib therapy in the NSCLC Expansion Cohort, prior erlotinib therapy will not be exclusionary
- History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
- Pregnant or breast-feeding females
- Gastrointestinal (GI) abnormalities including inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer, or prior surgical procedures affecting absorption
- Ocular inflammatory or infectious condition that is not completely resolved prior to registration
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
- Any type of active seizure disorder
- Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing
- Use of strong or moderate CYP3A4 or CYP1A2 inhibitors/inducers, with the exception of low-dose steroids, within 14 days prior to Day 1 dosing
- Use of proton pump inhibitors within 14 days prior to day 1 dosing
- Symptomatic brain metastases that are not stable, require steroids, or that have required radiation within the last 28 days
- Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Schedule 1
OSI-906 is administered on Days 1-3 every 7 days.
Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
|
somministrato per via orale
Altri nomi:
administered orally
|
Sperimentale: Schedule 2
OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
|
somministrato per via orale
Altri nomi:
administered orally
|
Sperimentale: Schedule 3
OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
|
somministrato per via orale
Altri nomi:
administered orally
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib
Lasso di tempo: 21 days
|
21 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Safety profile, Pharmacokinetic profile, pharmacodynamic activity, Preliminary antitumor activity
Lasso di tempo: 3 years
|
3 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Sr. Medical Director, Astellas Pharma Global Development
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- OSI-906-103
- 2008-001743-20 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tumori solidi avanzati
-
Rush University Medical CenterCompletatoAdvanced Cardiac Life Support, rianimazione cardiopolmonare, volume corrente, ventilazione manualeStati Uniti
-
The Leeds Teaching Hospitals NHS TrustAttivo, non reclutanteFerite e lesioni | Chirurgia | Riabilitazione | Disturbo ortopedico | Misure di esito riferite dal paziente | Valutazione della disabilità | Recupero della funzione | Trauma multiplo/lesioni | Centri traumatologici | Indici di gravità del trauma | Advanced Trauma Life Support CareRegno Unito
-
Advanced BionicsCompletatoPerdita dell'udito da grave a profonda | negli utenti adulti di Advanced Bionics HiResolution™ Bionic Ear SystemStati Uniti
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California e altri collaboratoriCompletatoCarcinoma polmonare non a piccole celluleStati Uniti
-
PfizerCompletatoCarcinoma, polmone non a piccole celluleStati Uniti
-
M.D. Anderson Cancer CenterCompletato
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatoCancro del polmone non a piccole cellule metastatico | Cancro del polmone non a piccole cellule ricorrenteStati Uniti
-
University of ChicagoNational Cancer Institute (NCI)CompletatoMesotelioma peritoneale malignoStati Uniti
-
PharmaMarCompletatoTumori solidi maligni avanzatiSpagna, Stati Uniti
-
Tragara Pharmaceuticals, Inc.CompletatoCarcinoma polmonare non a piccole cellule ricorrenteStati Uniti
-
New Mexico Cancer Care AllianceCompletatoTumori maligni solidi avanzatiStati Uniti
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.CompletatoCarcinoma, polmone non a piccole celluleStati Uniti
-
Merck Sharp & Dohme LLCCompletatoCarcinoma, polmone non a piccole cellule